Research background · Updated November 1, 2026
Tesamorelin Research: Publications, Study Types and Background
Short answer
Tesamorelin is listed as synthetic analogue of human growth hormone-releasing hormone, GHRH(1-44). As of November 1, 2026, PubMed indexes 95 records matching Tesamorelin, the earliest from 2006; 20 were published in 2021–2025 and 33 are reviews. ClinicalTrials.gov lists 24 registered studies matching the compound.
- PubMed records
- 95
- Earliest record
- 2006
- Published 2021–2025
- 20
- Reviews
- 33
- Animal-only studies
- 1
- Registered studies
- 24
Publications per year, 2006–2025
40 records in 2016–2025 against 46 in 2006–2015; the busiest year was 2011, with 12.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 7 |
| 2011 | 12 |
| 2012 | 8 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 4 |
Study types
| All PubMed records | 95 |
|---|---|
| Reviews | 3335% |
| Animal studies (no human subjects indexed) | 11% |
| Indexed as clinical trials | 2324% |
| Registered on ClinicalTrials.gov | 24 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 7 of the most-cited and most recent Tesamorelin papers report, in their own authors’ terms. Each line links the paper it came from.
This narrative review identifies tesamorelin, with bremelanotide, as among the most clinically established peptides it covers, with regulatory approval for selected indications, while noting that safety data across peptide classes are limited by short follow-up and small samples.
ReviewVasylieva V 2026Sexual medicine reviewsPMID 42862021
This review of growth hormone in aging men states that tesamorelin, a GHRH agonist, restores normal GH pulsatility and amplitude, selectively reduces visceral fat, intima media thickness and triglycerides, and improves cognitive function in older persons.
ReviewSattler FR 2013Best practice & research. Clinical endocrinology & metabolismPMID 24054930
In a randomized, double-blind trial in people with HIV and non-alcoholic fatty liver disease, tesamorelin was associated with a greater reduction in hepatic fat fraction than placebo, with no difference in fasting glucose or HbA1c; the authors call for longer-term histology studies.
HumansStanley TL 2019The lancet. HIVPMID 31611038
In a randomized, placebo-controlled trial in HIV-infected patients with abdominal fat accumulation, tesamorelin was associated with reductions in visceral fat and modest reductions in liver fat; fasting glucose rose early, but later glucose changes were not significant.
HumansStanley TL 2014JAMAPMID 25038357
In a randomized, placebo-controlled trial in adults with mild cognitive impairment and healthy older adults, tesamorelin was associated with a favorable effect on cognition, mainly executive function, plus higher IGF-1 and lower percent body fat; mild adverse events were more common than with placebo.
HumansBaker LD 2012Archives of neurologyPMID 22869065
In a pooled analysis of two phase 3 placebo-controlled trials in HIV patients with excess abdominal fat, tesamorelin was associated with reduced visceral adipose tissue, triglycerides and cholesterol ratio, without clinically meaningful changes in glucose parameters, and was generally well tolerated.
HumansFalutz J 2010The Journal of clinical endocrinology and metabolismPMID 20554713
In a randomized, placebo-controlled trial in HIV patients with abdominal fat accumulation, tesamorelin was associated with decreased visceral fat and improved lipid profiles; adverse events did not differ significantly between groups, though more tesamorelin patients withdrew because of an adverse event.
HumansFalutz J 2007The New England journal of medicinePMID 18057338
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 95 of the 95 records. They describe what the literature is about, not what Tesamorelin does.
- Growth Hormone-Releasing Hormone49 papers
- HIV Infections35 papers
- HIV-Associated Lipodystrophy Syndrome16 papers
- Non-alcoholic Fatty Liver Disease8 papers
- Human Growth Hormone8 papers
- Lipodystrophy8 papers
- Intra-Abdominal Fat7 papers
- Fatty Liver4 papers
Key papers
Earliest indexed record
Tomlinson B (2006). Current opinion in investigational drugs (London, England : 2000).
PMID 17086939Most-cited paper · 156 citations
Falutz J (2007). The New England journal of medicine.
PMID 18057338Most-cited #2 · 112 citations
Maggi P (2017). BMC infectious diseases.
PMID 28793863Most-cited #3 · 112 citations
Fraile JM (2021). Drug design, development and therapy.
PMID 34588764
Citation counts from NIH iCite, among the 95 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Synonyms and codes | TH9507 |
|---|---|
| Description | Synthetic analogue of human growth hormone-releasing hormone, GHRH(1-44) |
| CAS number | 218949-48-5 |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5136 g/mol |
As published by Vanta Labs, with its sources, on the Tesamorelin page.
How these numbers were counted
- PubMed search, run November 1, 2026:
tesamorelin[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
tesamorelinre-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use Tesamorelin outside a laboratory.
Wholesale supply
Tesamorelin for research, documented lot by lot.
5mg, 10mg vials. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
Tesamorelin research questions
How much research has been published on Tesamorelin?
PubMed indexes 95 records matching Tesamorelin (searched November 1, 2026), including 33 reviews and 23 records indexed as clinical trials. 20 were published in the five years 2021–2025.
When was Tesamorelin first described in the literature?
The earliest PubMed record matching Tesamorelin is from 2006 (Tomlinson B, Current opinion in investigational drugs (London, England : 2000), PMID 17086939).
What topics does the Tesamorelin literature cover?
The subject headings PubMed indexers most often marked as a main topic of Tesamorelin papers are Growth Hormone-Releasing Hormone, HIV Infections, HIV-Associated Lipodystrophy Syndrome, Non-alcoholic Fatty Liver Disease. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
What is the regulatory status of Tesamorelin?
The material supplied here is a research chemical. It is not a drug product and is not for human or veterinary use.
Is Tesamorelin sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy Tesamorelin wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.